Loading…
Calidi Biotherapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in CLDI.
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $18.72 | $220.80 | $2,899.20 | $19,526.40 | |
| P/S | — | — | — | — | 8114.7x |
| P/B | — | 2.2x | 15.6x | — | — |
| EPS | -$95.20 | -$571.20 | -$3,327.36 | -$1,359.66 | |
| Profit margin | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NXGLNexgel Inc | $0.35 | — | 0.7x | — | -115.06% | $3.43M |
| TNONTenon Medical, Inc. | $5.00 | — | — | — | -551.19% | $3.34M |
| UPCUniverse Pharmaceuticals INC | $4.90 | — | 0.0x | — | -3.50% | $3.25M |
| SXTP60 Degrees Pharmaceuticals Inc | $1.03 |
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Company description provided by Yahoo Finance.
| — |
| — |
| -56504.44% |
| ROE | — | -529.56% | -1443.48% | — | — |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| -332.85% |
| $3.62M |
| RDGTRidgetech Inc. | $1.00 | — | 0.0x | — | -3.55% | $3.63M |
| CALCCalciMedica, Inc. | $0.46 | — | 2.6x | — | -365.70% | $3.17M |